Welcome to Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. (“OAPI”) is part of the Otsuka Group (“Otsuka”).
 

Otsuka: A Diversified Global Group of Companies

Otsuka is a diversified group of companies with many lines of business that encompass pharmaceuticals, nutraceuticals, consumer products, medical devices, hospital infusion and chemicals. Otsuka includes 153 companies and 36,000 employees in 23 countries and regions around the world.  The Otsuka Group generated $9.7 B in net sales in 2008. Otsuka America Pharmaceutical, Inc. (OAPI) is a small company that is part of the Otsuka group of companies. OAPI was established in the US in 1989 and is responsible for all pharmaceutical and medical device commercial activities in North America.

OAPI Business Foundation, Vision and Focus

OAPI has built a solid foundation on Otsuka-developed products and will continue to build on this foundation to achieve its corporate vision: A strong and highly competitive organization capable of successfully launching our own products for better patient outcomes.

In 2009, OAPI is taking on greater responsibility for driving the growth of ABILIFY^® (aripiprazole)¹ in the US. We will maximize growth within the psychiatric community by building a strong neuroscience organization. OAPI is also focused on growing its oncology, hospital, and medical device businesses.
 

Pioneering Science: Driving unconventional thinking and action

Otsuka is committed to the “greater good” as demonstrated by the investments made to develop compounds in therapeutic areas that may not yield significant financial results. Examples include research investments in tuberculosis, which affects millions of patients in Africa and Asia, and the development of a compound for hyponatremia and, potentially, for polycystic kidney disease (PKD). Both hyponatremia and PKD have a small prevalence and might otherwise be ignored. The history of Otsuka’s development activities demonstrates its commitment to a long-term approach. Otsuka develops drugs and treatments by understanding patients’ and doctors’ unmet medical needs, and taking the time needed to explore the full potential of a compound. ABILIFY^® (aripiprazole)¹ was in development for 22 years prior to commercialization and today is used by over 3 million patients.
 

OAPI Offers a Unique Culture

At OAPI, each employee’s ideas are welcomed and considered, regardless of his or her role or level in the organization. OAPI offers a pay for performance environment. Once onboard, Otsuka’s principle of “jissho shugi” (demonstrating excellence to be considered for greater responsibility) ensures people grow and are rewarded. Consistent, candid and honest performance feedback coupled with leadership development opportunities present each employee with opportunities to meet their full potential. OAPI is committed to developing, attracting and retaining top talent in the pharmaceutical industry. We all share a common drive to make a difference by working together to grow our business and promote better health.

1 Please see FULL PRESCRIBING INFORMATION including Boxed WARNINGS for ABILIFY.

0109W-0602